trending Market Intelligence /marketintelligence/en/news-insights/trending/lic_eb135eNx6919QIf5Vw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

ProMetric's application for plasminogen replacement therapy accepted by US FDA

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

ProMetric's application for plasminogen replacement therapy accepted by US FDA

ProMetic Life Sciences Inc.'s biologics license application for plasminogen replacement therapy Ryplazim was accepted by the U.S. Food and Drug Administration.

Plasminogen is a protein synthesized by the liver that circulates in the blood. It is vital in wound healing, cell migration, tissue remodeling, angiogenesis and embryogenesis.

The most common condition linked to plasminogen deficiency is ligneous conjunctivitis, which is characterized by thick, woody growths on the conjunctiva of the eye, and if left untreated, can lead to corneal damage and blindness.

The U.S. FDA granted Ryplazim a priority review status, with approval expected April 14, 2018. The therapy was previously granted fast track, orphan drug and rare pediatric disease designations by the agency.

ProMetic previously reported data from a phase 2/3 trial, which showed that the treatment consistently replaced and maintained plasminogen concentration at an appropriate level and resolved all lesions in patients with congenital plasminogen deficiency.